Warning issued on non-response rates.
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects*; D015337:Multicenter Studies as Topic; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D000068698:Tenofovir; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D000099227:Abacavir